Tramadol Reformulations Highlight Pain Challenges and Opportunities
Executive Summary
While reformulating existing drugs can sometimes look like a low risk opportunity, since active substances are already deemed safe and effective, the task is often more complex. The race to develop extended release versions of the now-generic opioid tramadol showcase these technological, clinical and regulatory challenges, while demonstrating that for those who succeed, the upside can be great. A look at Pudue's deal with Labopharm and JNJ's deal with Biovail.
You may also be interested in...
Infinity/Purdue: The Challenge of Reprising Roche/Genentech
Infinity's "Big Brother" deal with the privately held affiliates Purdue and Mundipharma comes closest of any recent deal to replicating the structure of the Genentech/Roche relationship -- swapping the majority of a biotech's pipeline to a well-heeled partner in return for independence from the capital markets and enough commercial upside to deliver a long-term return for investors. But the idiosyncrasies of the Purdue/Mundipharma ownership and structure, and the recent stormy history that opened minds to the possibility of such a deal, show why further iterations of the model will remain a rarity.
Infinity/Purdue: The Challenge of Reprising Roche/Genentech
Infinity's "Big Brother" deal with the privately held affiliates Purdue and Mundipharma comes closest of any recent deal to replicating the structure of the Genentech/Roche relationship -- swapping the majority of a biotech's pipeline to a well-heeled partner in return for independence from the capital markets and enough commercial upside to deliver a long-term return for investors. But the idiosyncrasies of the Purdue/Mundipharma ownership and structure, and the recent stormy history that opened minds to the possibility of such a deal, show why further iterations of the model will remain a rarity.
NicOx Eyes Continued Comeback with Second Pfizer Deal
In early March, Pfizer licensed all ophthalmic rights to NicOx's nitric-oxide donating technology platform, just months after selecting and licensing a preclinical glaucoma candidate from the firms' previous, more narrow, collaboration. The moves have buoyed NicOx, which has been in the investor doghouse since 2003 when AstraZeneca chose to discontinue development of the firm's lead product, which was in Phase II trials for osteoarthritis pain.